首页|期刊导航|中国动脉硬化杂志|PCSK9抑制剂对老年糖尿病合并急性冠脉综合征患者PCI术后远期预后的影响

PCSK9抑制剂对老年糖尿病合并急性冠脉综合征患者PCI术后远期预后的影响OA

Effects of PCSK9 inhibitors on long-term prognosis after PCI in elderly diabetic pa-tients complicated with acute coronary syndrome

中文摘要英文摘要

[目的]探讨前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂对老年糖尿病合并急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后 1 年再狭窄及 3 年主要不良心脑血管事件(MACCE)发生率的影响.[方法]将320 例老年糖尿病合并 ACS 患者随机分为常规治疗组和 PCSK9 抑制剂组,每组各160 例.常规治疗组于PCI 术后接受规范药物治疗,PCSK9 抑制剂组则在规范药物治疗的基础上加用 PCSK9 抑制剂,疗程为 1 年.观察两组患者的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDLC)、低密度脂蛋白胆固醇(LDLC)、脂蛋白(a)、高敏 C 反应蛋白(hs-CRP)、肿瘤坏死因子 α(TNF-α)、白细胞介素6(IL-6)等检验指标及 PCI 部位再狭窄发生率,并通过3 年随访对比分析主要终点(心肌梗死、心源性死亡、全因死亡)、次要终点(MACCE)的复合终点(心肌梗死、心源性死亡、缺血诱发的再次血运重建、支架内血栓、脑卒中)及心绞痛发生率、再次住院率.[结果]治疗 1年后,PCSK9 抑制剂组的 TC、TG、LDLC、脂蛋白(a)、hs-CRP、TNF-α、IL-6水平及再狭窄发生率均显著低于常规治疗组(P<0.05);3 年随访结果显示,PCSK9 抑制剂组的主要终点事件(心源性死亡、心肌梗死)、总 MACCE、支架内血栓、心绞痛复发及再次血运重建的发生率均显著低于常规治疗组(P<0.05).[结论]PCSK9 抑制剂可有效降低老年糖尿病合并 ACS 患者的血脂水平、抑制炎症反应,同时降低 PCI 术后 1 年再狭窄发生率及 3 年 MACCE 发生率.

Aim To investigate the effects of proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors on the incidence of restenosis 1 year and major adverse cardiovascular and cerebrovascular events(MACCE)3 years after percutaneous coronary intervention(PCI)in elderly patients with diabetes and acute coronary syndrome(ACS).Methods 320 elderly patients with diabetes and ACS were randomly divided into the conventional treatment group and PCSK9 inhibitor group,with 160 cases in each group.The conventional treatment group received standardized drug treat-ment after PCI,while the PCSK9 inhibitor group received PCSK9 inhibitor in addition to standardized drug treatment for a course of 1 year.The total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDLC),low den-sity lipoprotein cholesterol(LDLC),lipoprotein(a),high sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and other test indicators as well as the incidence of restenosis at PCI site were observed in the two groups of patients,and the primary endpoint(myocardial infarction,cardiac death,and all-cause death),the composite endpoint(myocardial infarction,cardiac death,ischemia-driven repeat revascularization,stent thrombosis,and stroke)of the secondary endpoint(MACCE)and the incidence of angina pectoris and hospital readmission were compara-tively analyzed through 3-year follow-up.Results After 1 year of treatment,the levels of TC,TG,LDLC,lipoprotein(a),hs-CRP,TNF-α,IL-6,and the incidence of restenosis in the PCSK9 inhibitor group were significantly lower than those in the conventional treatment group(P<0.05).The 3-year follow-up results showed that the primary endpoint events(car-diac death,myocardial infarction),total MACCE,stent thrombosis,angina recurrence,and repeat revascularization inci-dence in the PCSK9 inhibitor group were significantly lower than those in the conventional treatment group(P<0.05).Conclusion PCSK9 inhibitors can effectively reduce the blood lipid level,inhibit inflammatory reaction,and reduce the incidence of restenosis 1 year after PCI and MACCE 3 years after PCI in elderly patients with diabetes and ACS.

刘洋;王子函;薛斌;陈奇;姬劲锐;魏小云;杨庆宇;刘恒亮

河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002豫北医学院,河南省 新乡市 453500河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002河南中医药大学第五临床医学院 河南中医药大学郑州人民医院,河南省 郑州市 450002

医药卫生

糖尿病急性冠脉综合征经皮冠状动脉介入治疗前蛋白转化酶枯草溶菌素 9主要不良心脑血管事件远期预后

diabetesacute coronary syndromepercutaneous coronary interventionproprotein convertase subtilisin/kexin type 9main adverse cardiovascular and cerebrovascular eventslong-term prognosis

《中国动脉硬化杂志》 2026 (7)

679-685,7

河南省科技发展计划项目(222102310345)

10.20039/j.cnki.1007-3949.2026.07.010

评论